It is well established that impaired T-cell immune reconstitution is a major risk factor for CMV reactivation following allogeneic HSCT (allo-HSCT). 1, 2 Results of immune monitoring studies have generally shown that CMV-specific T-cell immune reconstitution is associated with the spontaneous resolution of CMV viraemia 3 and protection from recurrent or complicated CMV reactivation. [2] [3] [4] However, unlike solid-organ transplantation, the relationship between CMV-specific immune reconstitution and protection from a first episode of CMV reactivation is unclear in allo-HSCT with some 5, 6 but not all 2,7 studies showing protection. As CMV-specific T-cell immune reconstitution is influenced by both homoeostatic proliferation and antigen-driven expansion, we hypothesise that the predictive value of CMV-specific immune monitoring can be improved if these contrasting driving forces can be separated. In this report, we show that the selective reconstitution of CMVspecific immunity ahead of global T-cell immune reconstitution is associated with a significantly higher risk of subsequent CMV reactivation than CMV-specific immune reconstitution that is concordant with global immune reconstitution.
We recently reported the results of a prospective study where weekly CMV-specific immune monitoring was performed using a whole-blood functional assay, QuantiFERON-CMV (Cellestis, Carnegie, VIC, Australia), 8 which measures IFN-γ secretion in 1 mL of whole blood in response to 23 CMV peptide epitopes representing diverse MHC class I alleles. 9 This assay incorporates a phytohaemagglutinin-treated sample, which measures mitogen response and serves as a positive assay control. In allo-HSCT, where patients are often lymphopenic or have impaired lymphocyte function, the mitogen response correlates with lymphocyte count. 8 Although IFN-γ secretion alone does not capture all T-cell activity, the mitogen response provides some indication of global T-cell response as a context for CMV-specific immune reconstitution. Here, we present additional analysis on our previously published study 8 and show that CMV-specific immune reconstitution follows two patterns, which are distinguishable by their concordance or otherwise with mitogen response and these two patterns are associated with divergent risks for CMV reactivation.
Details on study subjects, virological monitoring and immunological monitoring are previously described. 8 Briefly, patients undergoing allo-HSCT at the Royal Brisbane and Women's Hospital, Australia, were prospectively enrolled. Either the donor or the recipient or both must be CMV seropositive. CMV DNA quantification and QuantiFERON-CMV were performed at least weekly up to day 100. CMV reactivation was defined as CMV DNA ⩾ 600 copies/mL. CMV-specific immune response was defined as being present if IFN-γ was ⩾ 0.2 IU/mL in (CMV peptide tubeÀ no stimulation tube), irrespective of mitogen response; and mitogen response was present if IFN-γ was ⩾ 0.5 IU/mL in (mitogen tube À no stimulation tube). Samples with neither CMVspecific nor mitogen response were considered indeterminate.
In the first 100 days post transplant, 31 of the 41 study patients developed CMV-specific immunity, four of whom had prior CMV reactivation. Of the 27 patients without prior CMV reactivation, 11 (41%) developed CMV reactivation after CMV-specific immune reconstitution. The risk of CMV reactivation was significantly higher in those who reconstituted CMV-specific immunity without prior or concurrent mitogen reactivity (8 of 13; 62%) compared with those with mitogen reactivity (3 of 14; 21%; P = 0.036, Fisher's exact test; Table 1 ). Furthermore, the temporal relationship between the development of a mitogen response and CMV-specific immunity correlated with CMV reactivation: patients who subsequently experienced CMV reactivation had a tendency to reconstitute CMV-specific immune response before mitogen response (mean of 27 days earlier), whereas the converse was true in patients without CMV reactivation (mean of 4 days later; P = 0.0051, t-test; Figure 1a ). In addition, the absence of a mitogen response before CMV reactivation was associated with a higher initial CMV growth rate (growth date 0.47/day vs 0.18/day; doubling time 1.5 vs 3.9 days; growth rate calculation per Cromer et al.
10
).
As the presence of a mitogen response strongly correlated with lymphocyte count (Figure 1b) , we studied the effect of lymphocyte count as a measure of global immune reconstitution and found that patients who reconstituted CMV-specific immunity without lymphocyte count recovery to ⩾ 700/μL also tended to have a higher rate of CMV reactivation than those with concurrent lymphocyte recovery, although the difference did not reach statistical significance (80% vs 32%; P = 0.13). We propose that low-level CMV reactivation can drive the selective reconstitution of CMV-specific immunity which, although protective of severe and recurrent CMV reactivation, cannot fully prevent the development of overt CMV DNAemia. This hypothesis is supported by two additional findings. Firstly, prior subclinical CMV DNAemia (o 600 copies/mL) was detected in 3 of the 13 patients without concurrent mitogen response as compared with 0 of the 14 patients with concurrent mitogen response (P = 0.10). Secondly, four of the eight patients who reactivated CMV (⩾600 copies/mL) in the group without mitogen response did so within a week of CMV-specific immune reconstitution, which suggested that low-level CMV replication was probably already in progress at the time of CMV-specific immune reconstitution and a driving force thereof. In contrast, none of the patients with concurrent mitogen response reactivated CMV within the first week, with time to reactivation ranging from 21 to 30 days. Hence, we propose that CMV-specific immune reconstitution that is accelerated relative to mitogen response can sometimes be an indicator of early low-level CMV reactivation and paradoxically herald overt reactivation, thus accounting for the apparent lack of protective effect. Although mitogen response is used as an indicator of global T-cell immune reconstitution in this retrospective analysis, it may not be the optimum assay going forward. The mitogen response as provided in the QuantiFERON-CMV kit is limited to the detection of IFN-γ-secreting T cells, correlates more closely with CD8 + than CD4 + T-cell count (Figure 1c) , and is not validated for the assessment of broader T-cell immunity. The use of alternative assays, such as T-cell subset enumeration or a validated functional assay such as the Immuknow assay, which measures ATP production by CD4 + T cells, 11 may be more informative. These limitations notwithstanding, our finding calls for the interpretation of CMV-specific immunity in the context of global T-cell immune reconstitution in future immune monitoring studies. + and CD8 + T-cell counts and mitogen response. Analysis was restricted to samples where T-cell enumeration and QuantiFERON-CMV assays were performed within 7 days of each other and the total lymphocyte counts at the time of the two assays were within 500 cells/μL of each other.
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